Lilly Reports Strong Fourth-Quarter and Full-Year 2018 Financial Results, Lowers 2019 EPS Guidance to Reflect the Pending Acquisition of Loxo Oncology
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/22/2026
- S&P 500, Nasdaq close lower, dragged by Alphabet and megacap tech; focus on Iran
- Oil settles down more 3% after US-Iran talks signal easing supply risks
- Micron surges 5.5% on blockbuster Anthropic AI deal ahead of earnings
- Alan Greenspan, influential former Federal Reserve chair, dies at 100
- Buy gold stocks as valuations are cheap amid macro tension: BofA
- CoreWeave trains DeepSeek-V3 in two minutes in MLPerf benchmark
- Needham Starts NeoVolta (NEOV) at Buy
- Spain's ex-transport minister sentenced to 24 years for corruption
- Li Auto Inc. (LI) Breaks Ground on Chips R&D and Production Base
- Exclusive-China robot-hand-building unicorn Linkerbot targets $6 billion valuation
Eli Lilly (LLY) PT Raised to $115 at Credit Suisse
February 7, 2019 7:59 AM ESTCredit Suisse analyst Vamil Divan raised the price target on Eli Lilly (NYSE: LLY) to $115.00 (from $112.00) while maintaining a Neutral rating following the company's 4Q earnings report. Overall, 4Q18 was mixed, as revenues beat expectations but EPS missed forecasts by a... More
Eli Lilly (LLY) PT Raised to $143 at Cantor Fitzgerald
February 6, 2019 1:28 PM ESTCantor Fitzgerald analyst Louise Chen raised the price target on Eli Lilly (NYSE: LLY) to $143.00 (from $128.00) while maintaining a Overweight rating.
Chen commented, "Post a modest 4Q18 EPS miss, we maintain our OW rating and increase our 12 month PT to $143... More
Eli Lilly & Co. (LLY) Misses Q4 EPS by 1c, Revenue Beats, FY19 EPS Guidance Misses
February 6, 2019 6:27 AM ESTEli Lilly & Co. (NYSE: LLY) reported Q4 EPS of $1.33, $0.01 worse than the analyst estimate of $1.34. Revenue for the quarter came in at $6.44 billion versus the consensus estimate of $6.28 billion.
GUIDANCE:
Eli Lilly & Co. sees FY2019 EPS of $5.55-$5.65, versus the... More
